|
|||||
|
|
| 玻璃体内注射康柏西普对糖尿病性黄斑水肿患者黄斑区视网膜血管密度和中心凹无血管区面积的影响 | |
| 引用本文： | 马若璇,冉振龙,张月玲,顾朝辉. 玻璃体内注射康柏西普对糖尿病性黄斑水肿患者黄斑区视网膜血管密度和中心凹无血管区面积的影响[J]. 眼科新进展, 2020, 0(4): 365-368. DOI: 10.13389/j.cnki.rao.2020.0084 |
| 作者姓名： | 马若璇 冉振龙 张月玲 顾朝辉 |
| 作者单位： | 067000 河北省承德市，承德医学院研究生学院（马若璇）；071000 河北省保定市，保定市第一中心医院眼二科（冉振龙，张月玲，顾朝辉） |
| 摘 要： | 目的探讨玻璃体内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物康柏西普治疗糖尿病性黄斑水肿(diabetic macular edema,DME)患者对黄斑区视网膜微循环的影响。方法应用光学相干断层扫描血管成像(optical coherence tomography angiography,OCTA)观察36例DME患者,在接受连续3个月每月1次玻璃体内注射0.5 mg康柏西普治疗前后最佳矫正视力(BCVA)、中心视网膜厚度(central retinal thickness,CRT)及黄斑区浅层和深层视网膜毛细血管的血管密度(vessel density,VD)和中心凹无血管区(foveal avascular zone,FAZ)面积的变化。结果 DME患者康柏西普玻璃体内注射治疗前BCVA为0.26±0.02,3次注射治疗后BCVA分别为0.42±0.04、0.51±0.04及0.54±0.04,治疗后BCVA较治疗前显著提高;治疗前CRT为(472.42±9.68)μm,3次注射治疗后CRT分别为(339.33±6.... |
| 关 键 词： | 糖尿病性黄斑水肿 康柏西普 光学相干断层扫描血管成像 中心凹无血管区面积 血管密度 |
Effect of intravitreal injection of Conbercept for treatment of diabetic macular edema on retinal vessel density at macular region and foveal avascular zone area |
|
| MA Ruoxuan,RAN Zhenlong,ZHANG Yueling,GU Zhaohui. Effect of intravitreal injection of Conbercept for treatment of diabetic macular edema on retinal vessel density at macular region and foveal avascular zone area[J]. Recent Advances in Ophthalmology, 2020, 0(4): 365-368. DOI: 10.13389/j.cnki.rao.2020.0084 | |
| Authors: | MA Ruoxuan RAN Zhenlong ZHANG Yueling GU Zhaohui |
| Affiliation: | 1.Graduate school of Chengde Medical College，Chengde 067000，Hebei Province，China2.Department of Ophthalmology，Baoding First Central Hospital，Baoding 071000， Hebei Province，China |
| Abstract: | Objective To investigate the effect of the intravitreal injection of anti-vascular endothelial growth factor(VEGF)Conbercept for treatment of diabetic macular edema(DME)on macular retinal microcirculation.Methods The changes of best corrected visual acuity(BCVA),central retinal thickness(CRT),vessel density(VD)and foveal avascular zone(FAZ)area in the superficial and deep retinal capillary of 36 DME patients were observed by optical coherence tomography angiography(OCTA)before and after intravitreal injection of 0.5 mg Conbercept once a month for 3 consecutive months.Results BCVA was 0.26±0.02 for DME patients before receiving anti-VEGF treatment,and 0.42±0.04,0.51±0.04 and 0.54±0.04 after three times of injection,respectively.BCVA after treatment was significantly higher than that before treatment.CRT was(472.42±9.68)μm before treatment,and(339.33±6.73)μm,(320.89±7.60)μm and(300.14±5.60)μm after 3 times of treatment.CRT after treatment was significantly lower than that before treatment.No statistical differences were observed in BCVA and CRT between before and after treatment(both P<0.05).VD in the superficial retinal capillary was(44.27±0.04)%for DME patients before treatment,(44.28±0.04)%,(44.32±0.04)%and(44.32±0.04)%after 3 times of treatment;VD in the deep retinal capillary was(52.96±0.04)%,(52.94±0.04)%,(52.87±0.04)%and(52.87±0.04)%after 3 times of treatment.FAZ at superficial layer was(0.56±0.08)mm2 before treatment,(0.56±0.08)mm2,(0.56±0.08)mm2 and(0.56±0.08)mm2 after 3 times of treatment.FAZ at deep layer was(0.75±0.10)mm2 before treatment,and(0.75±0.09)mm2,(0.75±0.09)mm2 and(0.75±0.09)mm2 after 3 times of treatment.No statistical differences were observed in VD and FAZ areas at superficial layer and deep layer between before and after treatment(all P>0.05).Conclusion Intravitreal injection of 0.5 mg Conbercept once a month for 3 months can effectively improve BCVA and reduce CRT of DME patients,and have no significant effect on VD and FAZ area of retinal capillaries. |
| Keywords: | diabetic macular edema Conbercept optical coherence tomography angiography foveal avascular zone vessel density |
| 本文献已被 维普 等数据库收录！ | |
| 点击此处可从《眼科新进展》浏览原始摘要信息 | |
| 点击此处可从《眼科新进展》下载免费的PDF全文 | |